Newron Pharmaceuticals SpA (NWPHF)
OTHER OTC:NWPHF

Newron Pharmaceuticals SpA (NWPHF) Income Statement

9 Followers

Newron Pharmaceuticals SpA Income Statement

Last quarter (Q4 2022), Newron Pharmaceuticals SpA's total revenue was €―, a decrease of ― from the same quarter last year. In Q4, Newron Pharmaceuticals SpA's net income was €―. See Newron Pharmaceuticals SpA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
-€ 6.09M€ 5.76M€ 5.26M€ 7.04M€ 4.03M
Cost of Revenue
---€ 295.00K€ 1.43M€ 1.37M
Gross Profit
---€ 4.96M€ 5.61M€ 2.65M
Operating Expense
-€ 19.40M€ 18.12M€ 23.32M€ 26.51M€ 17.63M
Operating Income
-€ -13.30M€ -12.36M€ -18.07M€ -20.90M€ -14.98M
Net Non Operating Interest Income Expense
-€ -4.29M€ -2.73M€ -1.38M€ -473.00K€ -253.00K
Other Income Expense
------
Pretax Income
-€ -17.47M€ -14.88M€ -19.62M€ -20.16M€ -15.02M
Tax Provision
-€ 21.00K€ 17.00K€ 1.38M€ 45.00K€ 16.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-€ -17.49M€ -14.90M€ -21.00M€ -20.21M€ -15.04M
Basic EPS
-€ -0.98€ -0.84€ -1.18€ -1.13€ -0.84
Diluted EPS
-€ -0.98€ -0.84€ -1.18€ -1.13€ -0.84
Basic Average Shares
-€ 17.84M€ 17.84M€ 17.84M€ 17.84M€ 17.84M
Diluted Average Shares
-€ 17.84M€ 17.84M€ 17.84M€ 17.84M€ 17.84M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
-€ 160.00K€ 115.00K€ 80.00K€ 87.00K€ 321.00K
Total Expenses
-€ 19.40M€ 18.12M€ 23.32M€ 27.94M€ 19.00M
Net Income From Continuing And Discontinued Operation
-€ -17.49M€ -14.90M€ -21.00M€ -20.21M€ -15.04M
Normalized Income
-€ -17.49M€ -14.90M€ -21.00M€ -21.14M€ -15.04M
Interest Expense
-€ 3.95M€ 2.92M€ 2.24M€ 664.00K€ 385.00K
EBIT
-€ -13.53M€ -11.97M€ -17.38M€ -19.50M€ -14.63M
EBITDA
-€ -13.32M€ -11.76M€ -17.16M€ -19.29M€ -14.44M
Currency in EUR

Newron Pharmaceuticals SpA Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis